CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Target Price of $10.44 According to Analysts

CAMP4 Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are moderately positive on CAMP4 Therapeutics: 11 brokerages give the stock an average “Moderate Buy” rating, with an average 12-month price target of $10.44.
  • Recent research calls varied: Oppenheimer initiated coverage with an “outperform” rating and a $15 target, while Chardan Capital lowered its target to $6 but maintained a “buy” rating.
  • CAMP4 reported a quarterly loss of $0.37 per share, missing the $0.20 loss analysts expected, on revenue of $1.9 million. The CFO bought 10,000 shares, while a director sold 400,000 shares.
  • Five stocks we like better than CAMP4 Therapeutics.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $10.44.

Several equities research analysts recently issued reports on CAMP shares. Chardan Capital cut their price objective on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, September 29th. Zacks Research upgraded shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Oppenheimer began coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They set an "outperform" rating and a $15.00 price target for the company. Needham & Company LLC assumed coverage on shares of CAMP4 Therapeutics in a research report on Thursday, October 15th. They set a "buy" rating and a $8.00 price target on the stock. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th.

Get Our Latest Stock Analysis on CAMP4 Therapeutics

CAMP4 Therapeutics Stock Performance

CAMP4 Therapeutics stock opened at $4.10 on Thursday. The stock has a 50-day moving average of $3.84 and a two-hundred day moving average of $4.20. CAMP4 Therapeutics has a one year low of $2.90 and a one year high of $7.75. The stock has a market cap of $257.29 million, a PE ratio of -1.92 and a beta of 0.28.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.17). CAMP4 Therapeutics had a negative return on equity of 182.39% and a negative net margin of 2,276.33%. The business had revenue of $1.90 million for the quarter. As a group, sell-side analysts predict that CAMP4 Therapeutics will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, CFO Kelly Gold purchased 10,000 shares of the firm's stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Andrew J. Schwab sold 400,000 shares of the company's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 432,028 shares of company stock valued at $1,760,126. 21.69% of the stock is owned by insiders.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAMP. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics during the second quarter valued at about $78,000. Deutsche Bank AG purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $138,000. Empowered Funds LLC acquired a new position in shares of CAMP4 Therapeutics in the 3rd quarter worth approximately $220,000. Landscape Capital Management L.L.C. acquired a new position in shares of CAMP4 Therapeutics in the 3rd quarter worth approximately $264,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $365,000.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company's research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Further Reading

Analyst Recommendations for CAMP4 Therapeutics (NASDAQ:CAMP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CAMP4 Therapeutics Right Now?

Before you consider CAMP4 Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CAMP4 Therapeutics wasn't on the list.

While CAMP4 Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines